Navigation Links
Marshall Edwards Announces Initiation of Phase I Clinical Trial of Lead Oncology Drug Candidate ME-143
Date:9/8/2011

www.clinicaltrials.gov/">www.clinicaltrials.gov.

About ME-143

ME-143 is the lead oncology drug candidate from Marshall Edwards' NADH oxidase inhibitor program. It was derived from a proprietary isoflavone technology platform that has generated a number of compounds with anti-proliferative activity against tumor cells in laboratory studies. In pre-clinical studies, ME-143 has demonstrated potent activity against a number of tumor cell lines, including breast, colorectal and ovarian. In addition to broad single-agent activity, ME-143 has also shown an ability to enhance the cytotoxic effects of chemotherapy in pre-clinical studies. Marshall Edwards owns exclusive worldwide rights to ME-143. ME-143 is an investigational drug and has not been approved by the FDA for commercial distribution in the U.S. or other countries.

About Marshall Edwards

Marshall Edwards, Inc. (Nasdaq: MSHL) is a San Diego-based oncology company focused on the clinical development of novel anti-cancer therapeutics. The Company's lead programs focus on two families of small molecules that result in the inhibition of tumor cell metabolism. The first and most advanced is a NADH oxidase inhibitor program that includes lead candidate ME-143. The second is a mitochondrial inhibitor program that includes lead candidate ME-344. The Company initiated a Phase I clinical trial of intravenous ME-143 in September 2011 and expects to submit an IND application for ME-344 by the first quarter of 2012. For more information, please visit www.marshalledwardsinc.com.

Under U.S. law, a new drug cannot be marketed until it has been investigated in clinical trials and approved by the FDA as being safe and effective for the intended use. Statements included in this press release that are not historical in nature are "forward-looking stat
'/>"/>

SOURCE Marshall Edwards, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Marshall Edwards Announces FDA Approval of Investigational New Drug Application for Lead Candidate ME-143
2. Marshall Edwards Announces Publication of Pre-Clinical Study Showing Activity in Chemotherapy-Resistant Ovarian Cancer Stem Cells
3. Marshall Edwards Announces Publication of Pre-Clinical Studies in Pancreatic Cancer
4. Marshall Edwards Announces Closing of Asset Purchase Agreement With Novogen
5. Marshall Edwards Announces Private Placement
6. Marshall Edwards Announces Publication of Phase II Clinical Trial Results Highlighting Activity of Intravenous Phenoxodiol
7. Marshall Edwards Receives Positive Response From NASDAQ
8. Marshall Edwards to Host Annual Meeting of Stockholders
9. Marshall Edwards Receives NASDAQ Notice Of Non-Compliance; Intends To Request Hearing
10. Marshall Edwards Announces Presentation of New Data Showing Activity in Chemotherapy-Resistant Ovarian Cancer Cells
11. Medical Device Consultants, Inc. Welcomes Brian Edwards, Senior Regulatory Staff Consultant
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/17/2014)... , Oct. 17, 2014  Talyst, a market ... 2014 LeadingAge Annual Meeting in Nashville, TN. ... System, the market leading solution for onsite, remote medication ... term care facilities to safely and securely dispense medication ... to first dose, helps ensure that the correct medication ...
(Date:10/17/2014)... , Oct. 17, 2014  Ameritox SM , ... the appointment of Thomas Smith , M.D., as ... a field-based team offering scientific resources for healthcare providers, ... has held leadership positions at a variety of healthcare ... benefit both the pain and behavioral health sides of ...
(Date:10/17/2014)... 2014   DaVita HealthCare Partners Inc. ... nation,s largest and most innovative health care communities, ... the company,s award-winning, leadership development and cultural orientation ... from around the globe were in attendance for ... is a two-day one-of-a-kind experience for new and ...
Breaking Medicine Technology:Talyst Exhibits at LeadingAge Annual Meeting 2Ameritox Appoints New Chief Medical Officer 2DaVita HealthCare Partners Celebrates New-Teammate Training and Leadership Milestone 2DaVita HealthCare Partners Celebrates New-Teammate Training and Leadership Milestone 3
... Naurex Inc., a clinical-stage company developing innovative ... today announced that it has initiated a Phase II ... Glycine-site Functional Partial Agonist (GFPA) selective modulator of the ... therapy for patients who are not achieving an adequate ...
... 2011 Cempra Pharmaceuticals Inc. today announced that ... present at the 2011 Wells Fargo Healthcare Conference at ... Fernandes will provide an overview of the company,s two ... and other infections and TAKSTA™ for the oral treatment ...
Cached Medicine Technology:Naurex Initiates Phase II Clinical Trial of Novel Antidepressant GLYX-13 in Treatment-Resistant Depression 2Naurex Initiates Phase II Clinical Trial of Novel Antidepressant GLYX-13 in Treatment-Resistant Depression 3
(Date:10/20/2014)... New York, NY (PRWEB) October 20, 2014 ... to be introduced in the U.S., has a lot to ... time when our country recognizes the achievements and contributions of ... marks the anniversary for Punzoné, and today it shares its ... and take a trip to Italy - even if it ...
(Date:10/20/2014)... Maryland, USA (PRWEB) October 20, 2014 ... to track interventions? Here comes a wonderful app Metassessor ... mobile app development company helped its client “Intervention ... more efficiently. The app is designed for iOS 4.3 ... iPod touch. This app is optimized for iPhone 5. ...
(Date:10/19/2014)... October 20, 2014 The leading ... ( http://www.top10bestseohosting.com/go/iPage/ ) and GreenGeeks are the best ... platforms for those who want to buy high ... time. , The IT manager of Top10BestSEOHosting.com says, ... most recommended suppliers for everyone. A lot of ...
(Date:10/19/2014)... 19, 2014 Dr. Babatunde Osotimehin, Executive ... news of a ceasefire agreement that is expected to ... girls who were kidnapped from the north-eastern Nigerian town ... captivity long enough, and it is high time they ... Dr. Osotimehin. , "We owe it to these girls ...
(Date:10/19/2014)... Having been working in the garment industry for decades, ... According to James, one of the company’s top designers, many ... high-low skirts that add beauty to them. Chiffon floor length ... unveiled its new selection of 2014 long prom dresses. ... items are available in over 20 popular designs. The company ...
Breaking Medicine News(10 mins):Health News:Celebrate Italian Heritage Month With Authentic Cocktails from Punzoné: The Only Ultra Premium Line of Organic Imported Italian Vodka 2Health News:Celebrate Italian Heritage Month With Authentic Cocktails from Punzoné: The Only Ultra Premium Line of Organic Imported Italian Vodka 3Health News:Celebrate Italian Heritage Month With Authentic Cocktails from Punzoné: The Only Ultra Premium Line of Organic Imported Italian Vodka 4Health News:Metassessor App Launched: an RTI tool for Teachers & Parents 2Health News:Metassessor App Launched: an RTI tool for Teachers & Parents 3Health News:Top10BestSEOHosting.com Considers iPage And GreenGeeks As The Best Dedicated Server Hosting Suppliers 2Health News:2014 Long Prom Dresses From LunaDress Now Available In Over 20 Popular Designs 2
... Rochelle, NY -- The current issue of Medical ... Liebert, Inc., explores how the U.S. military is incorporating ... military personnel serving in the war zones and the ... issue is available online at http://www.liebertpub.com/acu . ...
... 4, 2012 As the pharmaceutical industry continues to ... protecting patients from counterfeit medicines, as well as the ... mounted. In an effort to encourage comprehensive public standards ... is proposing a set of recommended best practices that ...
... used extensively in Chinese traditional medicine that kill ... the leading causes of tooth loss in children and adults. ... , they say that these substances could have a role ... Stefan Gafner and colleagues explain that the dried root ...
... Weight loss surgery is not a cure for type 2 ... a new study published in the British Journal of ... to 80 per cent of diabetes patients have been cured ... that only 41 per cent of patients achieve remission using ...
... -- Arrogant people are less likely than humble people to ... Although personal factors (such as previous time commitments and ... how many people are watching) come into play, humility is ... helping hand, according to the study published online Jan. 2 ...
... a study that investigates the challenges of disseminating clinical research ... have found that fewer than half of a sample of ... Health (NIH) were published within 30 months of completing the ... issue of the British Medical Journal , which focuses ...
Cached Medicine News:Health News:Proposed standard offers best practices to help ensure pharmaceutical supply chain integrity 2Health News:Proposed standard offers best practices to help ensure pharmaceutical supply chain integrity 3Health News:Proposed standard offers best practices to help ensure pharmaceutical supply chain integrity 4Health News:Scientists reassess weight loss surgery for type 2 diabetes 2Health News:Need Help? Seek Out the Humble 2Health News:Many NIH-funded clinical trials go unpublished over 2 years after completion 2
Gentamicin is an aminoglycosidic antibiotic that inhibits bacterial growth by inhibiting protein synthesis. Gentamicin is used for prevention and elimination of bacterial contaminants in cell culture...
LB Agar plates with 10mM Magnesium Sulfate....
LB Agar plates with 0.1mM EDTA....
1% tryptone, 0.5% yeast extract, 1.0% Sodium Chloride. 1.5% agararose...
Medicine Products: